Adrenocortical carcinoma laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Ahmed Younes (talk | contribs) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AAM}} {{MAD}} | {{CMG}}; {{AE}} {{AAM}} {{MAD}} | ||
==Overview== | ==Overview== | ||
Patients with functional adrenocortical carcinoma may have elevated concentrations of serum [[cortisol]], [[aldosterone]], [[testosterone]] or [[estrogen]] and reduced concentration of plasma [[renin]] and [[potassium]]. | Patients with functional adrenocortical carcinoma may have elevated concentrations of [[serum]] [[cortisol]], [[aldosterone]], [[testosterone]] or [[estrogen]] and reduced concentration of plasma [[renin]] and [[potassium]]. | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
Laboratory findings | Laboratory findings consistent with adrenocortical carcinoma are: | ||
{| class="wikitable" | {| class="wikitable" | ||
| Line 25: | Line 25: | ||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | * [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | ||
* Serum [[estradiol]] in men and [[postmenopausal]] women | * Serum [[estradiol]] in men and [[postmenopausal]] women | ||
* A recent study has shown significant differences in [[steroid hormones]] precursor and metabolite profiles in the urine of patients with ACC compared | * A recent study has shown significant differences in [[steroid hormones]] precursor and metabolite profiles in the urine of patients with ACC compared to patients with [[Adrenocortical adenoma|benign adrenal tumors]]. | ||
|- | |- | ||
|'''Epinephrine'''<ref name="pmid21385478">{{cite journal| author=Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV| title=Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma. | journal=Int Braz J Urol | year= 2011 | volume= 37 | issue= 1 | pages= 35-40;discussion 40-1 | pmid=21385478 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21385478 }}</ref> | |'''Epinephrine'''<ref name="pmid21385478">{{cite journal| author=Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV| title=Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma. | journal=Int Braz J Urol | year= 2011 | volume= 37 | issue= 1 | pages= 35-40;discussion 40-1 | pmid=21385478 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21385478 }}</ref> | ||
| | | | ||
* [[Metanephrine]] and [[normetanephrine]] in plasma or 24-hour urine | * [[Metanephrine]] and [[normetanephrine]] in the plasma or 24-hour urine | ||
|- | |- | ||
|'''Aldosterone'''<ref name="pmid21917861">{{cite journal| author=Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA et al.| title=Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. | journal=J Clin Endocrinol Metab | year= 2011 | volume= 96 | issue= 12 | pages= 3775-84 | pmid=21917861 | doi=10.1210/jc.2011-1565 | pmc=3232629 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21917861 }}</ref> | |'''Aldosterone'''<ref name="pmid21917861">{{cite journal| author=Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA et al.| title=Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. | journal=J Clin Endocrinol Metab | year= 2011 | volume= 96 | issue= 12 | pages= 3775-84 | pmid=21917861 | doi=10.1210/jc.2011-1565 | pmc=3232629 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21917861 }}</ref> | ||
| | | | ||
* Low serum [[aldosterone]] concentrations, normal or high serum or urinary concentrations of aldosterone precursors | * Low serum [[aldosterone]] concentrations, normal or high serum or urinary concentrations of [[aldosterone]] precursors | ||
|} | |} | ||
Latest revision as of 16:43, 19 October 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma laboratory findings |
|
Risk calculators and risk factors for Adrenocortical carcinoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
Patients with functional adrenocortical carcinoma may have elevated concentrations of serum cortisol, aldosterone, testosterone or estrogen and reduced concentration of plasma renin and potassium.
Laboratory Findings
Laboratory findings consistent with adrenocortical carcinoma are:
| Hormonal disturbance | labs |
|---|---|
| Cortisol[1] |
|
| Steroids[2] |
|
| Epinephrine[3] |
|
| Aldosterone[4] |
|
References
- ↑ Dunlap NE, Grizzle WE, Siegel AL (1985). "Cushing's syndrome. Screening methods in hospitalized patients". Arch Pathol Lab Med. 109 (3): 222–9. PMID 3838451.
- ↑ Fassnacht M, Allolio B (2009). "Clinical management of adrenocortical carcinoma". Best Pract Res Clin Endocrinol Metab. 23 (2): 273–89. doi:10.1016/j.beem.2008.10.008. PMID 19500769.
- ↑ Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV (2011). "Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma". Int Braz J Urol. 37 (1): 35–40, discussion 40-1. PMID 21385478.
- ↑ Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA; et al. (2011). "Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors". J Clin Endocrinol Metab. 96 (12): 3775–84. doi:10.1210/jc.2011-1565. PMC 3232629. PMID 21917861.